MX360187B - Uso de polipeptidos derivados de pedf para promover la regeneración de músculo o tendón o arteriogénesis. - Google Patents

Uso de polipeptidos derivados de pedf para promover la regeneración de músculo o tendón o arteriogénesis.

Info

Publication number
MX360187B
MX360187B MX2015001721A MX2015001721A MX360187B MX 360187 B MX360187 B MX 360187B MX 2015001721 A MX2015001721 A MX 2015001721A MX 2015001721 A MX2015001721 A MX 2015001721A MX 360187 B MX360187 B MX 360187B
Authority
MX
Mexico
Prior art keywords
arteriogenesis
pedf
promoting muscle
derived polypeptides
tendon regeneration
Prior art date
Application number
MX2015001721A
Other languages
English (en)
Other versions
MX2015001721A (es
Inventor
Tsao Yeou-Ping
Ho Tsung-Chuan
Original Assignee
Mackay Memorial Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mackay Memorial Hospital filed Critical Mackay Memorial Hospital
Publication of MX2015001721A publication Critical patent/MX2015001721A/es
Publication of MX360187B publication Critical patent/MX360187B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente invención se refiere a un péptido sintético, que tiene una secuencia de amino ácidos que tiene 20-39 residuos de amino ácidos. El péptido sintético tiene cuando menos 80% de identidad de secuencia de amino ácido a SEQ ID NO:1, e incluye cuando menos 20 residuos consecutivos que tienen cuando menos 90% de identidad de secuencia de amino ácidos a los residuos 11-30 de SEQ ID NO:1. También se describen aquí composiciones farmacéuticas que contienen el péptido sintético; y aplicaciones de las mismas. De acuerdo a varias modalidades de la presente descripción, el péptido sintético es útil en promover regeneración de músculo o tendón, y/o arteriogénesis en un sujeto.
MX2015001721A 2012-08-09 2012-08-09 Uso de polipeptidos derivados de pedf para promover la regeneración de músculo o tendón o arteriogénesis. MX360187B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2012/079897 WO2014023007A1 (en) 2012-08-09 2012-08-09 Use of pedf-derived polypeptides for promoting muscle or tendon regeneration or arteriogenesis

Publications (2)

Publication Number Publication Date
MX2015001721A MX2015001721A (es) 2015-07-06
MX360187B true MX360187B (es) 2018-10-24

Family

ID=50067394

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015001721A MX360187B (es) 2012-08-09 2012-08-09 Uso de polipeptidos derivados de pedf para promover la regeneración de músculo o tendón o arteriogénesis.

Country Status (12)

Country Link
US (1) US9884012B2 (es)
EP (3) EP3342781B1 (es)
JP (1) JP6228977B2 (es)
KR (1) KR101801198B1 (es)
CN (1) CN104854129B (es)
AU (1) AU2012387503B2 (es)
BR (1) BR112015002828B1 (es)
CA (1) CA2882479C (es)
EA (1) EA033145B1 (es)
IL (1) IL237137B (es)
MX (1) MX360187B (es)
WO (1) WO2014023007A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012389654B2 (en) * 2012-09-17 2017-05-25 Mackay Memorial Hospital Use of PEDF-derived polypeptides for treating alopecia and/or hair depigmentation
US9815878B2 (en) 2012-09-19 2017-11-14 Mackay Memorial Hospital Use of PEDF-derived polypeptides for preventing and/or ameliorating skin aging
AU2012390210B2 (en) 2012-09-20 2017-06-29 Mackay Memorial Hospital Use of PEDF-derived polypeptides for treating osteoarthritis
KR20230169375A (ko) * 2016-10-07 2023-12-15 브림 바이오테크놀로지, 인코퍼레이티드 Pedf-유래 짧은 펩타이드를 포함하는 조성물 및 그것의 사용
JP2017165745A (ja) * 2017-04-19 2017-09-21 マクカイ メモリアル ホスピタル 筋肉若しくは腱再生又は動脈形成を促進するためのｐｅｄｆ由来のポリペプチドの使用
JP6522063B2 (ja) * 2017-08-10 2019-05-29 マクカイ メモリアル ホスピタル 脱毛症及び／又は毛髪色素脱失を治療するためのｐｅｄｆ由来のポリペプチドの使用
CN107602691A (zh) * 2017-08-22 2018-01-19 徐州医科大学 色素上皮衍生因子的衍生多肽系列对于保护缺血心肌的用途
TW202010513A (zh) * 2018-04-08 2020-03-16 全福生物科技股份有限公司 Pedf衍生之短肽在肌腱癒合中的應用
CN115364199A (zh) * 2021-05-19 2022-11-22 远大医药（中国）有限公司 包含pedf衍生的短肽的组合物及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060189519A1 (en) * 2002-09-26 2006-08-24 Karl Volz Anti-angiogenic fragments fo pigment epithelium-derived factor (pedf)
EP1986676A4 (en) * 2006-02-15 2009-11-04 Univ Yale Inc COMPOSITIONS AND METHODS USING PIGMENT EPITHELIUM DERIVED FACTOR (PEDF) PEPTIDE FRAGMENTS
ES2329636B2 (es) * 2006-02-17 2010-07-26 Universitat De Valencia, Estudi General (Participa Con El 70%) Uso del factor pedf para inducir la auto-renovacion de celulas madre.
US20110092427A1 (en) 2008-03-18 2011-04-21 National University Corporation Hokkaido Universit y Polypeptide and pharmaceutical composition containing the polypeptide
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
CN101544696A (zh) 2009-04-24 2009-09-30 焦春 含色素上皮衍生因子的复合物及其制备方法和应用
CN102183661B (zh) 2011-03-16 2014-05-28 天津宝瑞生物技术有限公司 蛋白质及蛋白质组在制备肝硬化诊断试剂中的应用
EP2508196B1 (en) 2011-03-23 2018-09-26 Mackay Memorial Hospital Use of PEDF-derived polypeptides for promoting stem cells proliferation and wound healing

Also Published As

Publication number Publication date
EP2882772A4 (en) 2016-01-27
IL237137B (en) 2019-01-31
CA2882479C (en) 2018-07-24
KR20150058177A (ko) 2015-05-28
CN104854129A (zh) 2015-08-19
EP2882772A1 (en) 2015-06-17
MX2015001721A (es) 2015-07-06
EA033145B1 (ru) 2019-09-30
BR112015002828A2 (es) 2017-08-15
JP6228977B2 (ja) 2017-11-15
AU2012387503A1 (en) 2015-03-19
KR101801198B1 (ko) 2017-11-24
US9884012B2 (en) 2018-02-06
EA201590329A1 (ru) 2015-07-30
CN104854129B (zh) 2019-12-31
IL237137A0 (en) 2015-04-30
EP3339317A1 (en) 2018-06-27
CA2882479A1 (en) 2014-02-13
EP3342781B1 (en) 2019-07-24
EP3342781A1 (en) 2018-07-04
NZ705492A (en) 2016-06-24
BR112015002828B1 (pt) 2022-09-13
WO2014023007A1 (en) 2014-02-13
EP2882772B1 (en) 2017-12-20
JP2015525786A (ja) 2015-09-07
US20160000862A1 (en) 2016-01-07
AU2012387503B2 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
MX360187B (es) Uso de polipeptidos derivados de pedf para promover la regeneración de músculo o tendón o arteriogénesis.
MY161773A (en) Amylin analogues and pharmaceutical compositions thereof
EP2528934A4 (en) AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
EA033399B1 (ru) Аналоги глюкагона с повышенной растворимостью и/или стабильностью и их применение
MX2014001372A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
MX2013004061A (es) Analogos de ciclosporina.
MX2017009595A (es) Compuestos antisenescentes y usos de los mismos.
MY173521A (en) Trpv4 antagonists
MX342171B (es) Peptido o complejo peptidico que se une a integrina ?2 y metodos y usos que implican a los mismos.
PH12016500101A1 (en) Protease-resistant peptide ligands
MX2013004062A (es) Analogos de ciclosporina.
ZA201803551B (en) Personal care composition comprising taurine, arginine, glycine
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
PH12014501200A1 (en) Bacteriophage gene 3 protein compositions and use as amyloid binding agents
MX2017007554A (es) Detergentes y agentes de limpieza que comprende una combinacion de amilasa y proteasa.
EP2552462A4 (en) CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
GB2517354A (en) Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy
EP3044229A4 (en) Novel peptides and analogs for use in the treatment of oral mucositis
PH12015500049B1 (en) Novel protein material
WO2013192238A3 (en) Compositions and methods for treatment of diabetes
EP2899198A4 (en) SYNTHETIC PNTX (19) -EPEPTIDES, PHARMACEUTICAL COMPOSITIONS AND USES
WO2014039074A3 (en) Therapeutic compositions and related methods
GB201118201D0 (en) Novel peptides
EP2569327A4 (en) EIF4E BINDING PEPTIDES

Legal Events

Date Code Title Description
FG Grant or registration